235 related articles for article (PubMed ID: 36130755)
41. Enteric-coated Mycophenolate Sodium therApy versus cyclophosphamide for induction of Remission in Microscopic PolyAngiitis (EMSAR-MPA trial): study protocol for a randomised controlled trial.
Li S; Yao S; Tie X; Shi X; Feng R; Su X; Wang L
BMJ Open; 2024 Mar; 14(3):e074662. PubMed ID: 38471694
[TBL] [Abstract][Full Text] [Related]
42. Biologics for childhood systemic vasculitis.
Akamine K; Punaro M
Pediatr Nephrol; 2019 Nov; 34(11):2295-2309. PubMed ID: 30203375
[TBL] [Abstract][Full Text] [Related]
43. Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
Unizony S; Lim N; Phippard DJ; Carey VJ; Miloslavsky EM; Tchao NK; Iklé D; Asare AL; Merkel PA; Monach PA; Seo P; St Clair EW; Langford CA; Spiera R; Hoffman GS; Kallenberg CG; Specks U; Stone JH
Arthritis Rheumatol; 2015 Feb; 67(2):535-44. PubMed ID: 25332071
[TBL] [Abstract][Full Text] [Related]
44. Immunosuppressive Therapies in Ear, Nose, and Throat Involvement in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results From a Multicenter Retrospective Cohort Study.
Krol RM; Schaap CM; Welsing PMJ; Klaasen R; Remmelts HHF; Hagen EC; Heijstek MW; Spierings J
J Rheumatol; 2023 Mar; 50(3):384-389. PubMed ID: 36243413
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of mycophenolate mofetil as a remission induction therapy in antineutrophil cytoplasmic antibody: associated vasculitis-a meta-analysis.
Kuzuya K; Morita T; Kumanogoh A
RMD Open; 2020 Apr; 6(1):. PubMed ID: 32371435
[TBL] [Abstract][Full Text] [Related]
46. Negative anti-neutrophil cytoplasm antibody at switch to maintenance therapy is associated with a reduced risk of relapse.
Morgan MD; Szeto M; Walsh M; Jayne D; Westman K; Rasmussen N; Hiemstra TF; Flossmann O; Berden A; Höglund P; Harper L;
Arthritis Res Ther; 2017 Jun; 19(1):129. PubMed ID: 28592297
[TBL] [Abstract][Full Text] [Related]
47. Dose-dependent Pharmacological Response to Rituximab in the Treatment of Antineutrophil Cytoplasmic Antibody-associated Vasculitis.
Springer JM; Funk RS
J Rheumatol; 2021 Nov; 48(11):1718-1724. PubMed ID: 34334366
[TBL] [Abstract][Full Text] [Related]
48. Reduced-dose versus high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: predefined 2-year follow-up study.
Furuta S; Nakagomi D; Kobayashi Y; Hiraguri M; Sugiyama T; Amano K; Umibe T; Kono H; Kurasawa K; Kita Y; Matsumura R; Kaneko Y; Ninagawa K; Hiromura K; Kagami SI; Inaba Y; Hanaoka H; Ikeda K; Nakajima H;
Ann Rheum Dis; 2024 Jan; 83(1):96-102. PubMed ID: 37734880
[TBL] [Abstract][Full Text] [Related]
49. Rituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.
Gopaluni S; Smith RM; Lewin M; McAlear CA; Mynard K; Jones RB; Specks U; Merkel PA; Jayne DR;
Trials; 2017 Mar; 18(1):112. PubMed ID: 28270229
[TBL] [Abstract][Full Text] [Related]
50. Rituximab for remission induction in recurrent ANCA-associated glomerulonephritis postkidney transplant.
Murakami C; Manoharan P; Carter-Monroe N; Geetha D
Transpl Int; 2013 Dec; 26(12):1225-31. PubMed ID: 24118474
[TBL] [Abstract][Full Text] [Related]
51. Risk factors for serious infections in ANCA-associated vasculitis.
Odler B; Riedl R; Gauckler P; Shin JI; Leierer J; Merkel PA; St Clair W; Fervenza F; Geetha D; Monach P; Jayne D; Smith RM; Rosenkranz A; Specks U; Stone JH; Kronbichler A;
Ann Rheum Dis; 2023 May; 82(5):681-687. PubMed ID: 36702528
[TBL] [Abstract][Full Text] [Related]
52. Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.
McGregor JG; Hogan SL; Kotzen ES; Poulton CJ; Hu Y; Negrete-Lopez R; Kidd JM; Katsanos SL; Bunch DO; Nachman PH; Falk RJ
Nephrol Dial Transplant; 2015 Apr; 30 Suppl 1(Suppl 1):i123-31. PubMed ID: 25805743
[TBL] [Abstract][Full Text] [Related]
53. Prolonged disease-free remission following rituximab and low-dose cyclophosphamide therapy for renal ANCA-associated vasculitis.
Mansfield N; Hamour S; Habib AM; Tarzi R; Levy J; Griffith M; Cairns T; Cook HT; Pusey CD; Salama AD
Nephrol Dial Transplant; 2011 Oct; 26(10):3280-6. PubMed ID: 21414973
[TBL] [Abstract][Full Text] [Related]
54. Rituximab for anti-neutrophil cytoplasmic antibodies-associated vasculitis: experience of a single center and systematic review of non-randomized studies.
Ayan G; Esatoglu SN; Hatemi G; Ugurlu S; Seyahi E; Melikoglu M; Fresko I; Ozdogan H; Yurdakul S; Hamuryudan V
Rheumatol Int; 2018 Apr; 38(4):607-622. PubMed ID: 29322343
[TBL] [Abstract][Full Text] [Related]
55. Reducing glucocorticoid duration in ANCA-associated vasculitis: A pilot trial.
Miloslavsky EM; Niles JL; Wallace ZS; Cortazar FB; Fernandes A; Laliberte K; Stone JH
Semin Arthritis Rheum; 2018 Oct; 48(2):288-292. PubMed ID: 29530330
[TBL] [Abstract][Full Text] [Related]
56. Treatment of antineutrophil cytoplasmic antibody-associated vasculitis with rituximab.
Cartin-Ceba R; Fervenza FC; Specks U
Curr Opin Rheumatol; 2012 Jan; 24(1):15-23. PubMed ID: 22089095
[TBL] [Abstract][Full Text] [Related]
57. A novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis.
Pepper RJ; McAdoo SP; Moran SM; Kelly D; Scott J; Hamour S; Burns A; Griffith M; Galliford J; Levy JB; Cairns TD; Gopaluni S; Jones RB; Jayne D; Little MA; Pusey CD; Salama AD
Rheumatology (Oxford); 2019 Feb; 58(2):260-268. PubMed ID: 30239910
[TBL] [Abstract][Full Text] [Related]
58. PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab.
van Dam LS; Dirikgil E; Bredewold EW; Ray A; Bakker JA; van Kooten C; Rabelink TJ; Teng YKO
Nephrol Dial Transplant; 2021 Jul; 36(8):1408-1417. PubMed ID: 32601673
[TBL] [Abstract][Full Text] [Related]
59. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.
De Groot K; Rasmussen N; Bacon PA; Tervaert JW; Feighery C; Gregorini G; Gross WL; Luqmani R; Jayne DR
Arthritis Rheum; 2005 Aug; 52(8):2461-9. PubMed ID: 16052573
[TBL] [Abstract][Full Text] [Related]
60. Low-dose rituximab as induction therapy for ANCA-associated vasculitis.
Takakuwa Y; Hanaoka H; Kiyokawa T; Iida H; Fujimoto H; Yamasaki Y; Yamada H; Kawahata K
Clin Rheumatol; 2019 Apr; 38(4):1217-1223. PubMed ID: 30680533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
